The effect of LSD and 2-bromo LSD on the DOPA accumulation after central and peripheral decarboxylase inhibition. 1975

G Hollunger, and S A Persson

LSD and BOL were found to be equally potent in increasing the rat brain DOPA accumulation after decarboxylase inhibition. However, at the doses selected, the DOPA levels after haloperidol and apomorphine were increased by LSD but not by BOL. It is suggested that this difference is due to LSD's activating effect on central serotoninergic receptors.

UI MeSH Term Description Entries
D008238 Lysergic Acid Diethylamide Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood. LSD,Lysergide,LSD-25,Lysergic Acid Diethylamide Tartrate,Acid Diethylamide, Lysergic,Diethylamide, Lysergic Acid,LSD 25
D008297 Male Males
D010646 Phentolamine A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease. Fentolamin,Phentolamine Mesilate,Phentolamine Mesylate,Phentolamine Methanesulfonate,Phentolamine Mono-hydrochloride,Regitine,Regityn,Rogitine,Z-Max,Mesilate, Phentolamine,Mesylate, Phentolamine,Methanesulfonate, Phentolamine,Mono-hydrochloride, Phentolamine,Phentolamine Mono hydrochloride
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D004295 Dihydroxyphenylalanine A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. Dopa,3,4-Dihydroxyphenylalanine,3-Hydroxy-DL-tyrosine,Dihydroxyphenylalanine Hydrochloride, (2:1),beta-Hydroxytyrosine,3 Hydroxy DL tyrosine,3,4 Dihydroxyphenylalanine,beta Hydroxytyrosine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013268 Stimulation, Chemical The increase in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical. Chemical Stimulation,Chemical Stimulations,Stimulations, Chemical
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D065105 Aromatic Amino Acid Decarboxylase Inhibitors Compounds and drugs that block or inhibit the enzymatic action of AROMATIC AMINO ACID DECARBOXYLASES. Pharmaceutical agents in this category are used in conjunction with LEVODOPA in order to slow its metabolism. Aromatic-L-Amino-Acid Decarboxylase Inhibitors,DOPA Decarboxylase Inhibitors,Dihydroxyphenylalanine Decarboxylase Inhibitors,Aromatic L Amino Acid Decarboxylase Inhibitors,Decarboxylase Inhibitors, Aromatic-L-Amino-Acid,Decarboxylase Inhibitors, DOPA,Decarboxylase Inhibitors, Dihydroxyphenylalanine,Inhibitors, Aromatic-L-Amino-Acid Decarboxylase,Inhibitors, DOPA Decarboxylase,Inhibitors, Dihydroxyphenylalanine Decarboxylase

Related Publications

G Hollunger, and S A Persson
May 1977, European journal of pharmacology,
G Hollunger, and S A Persson
May 1968, The Journal of pharmacology and experimental therapeutics,
G Hollunger, and S A Persson
April 1979, European journal of pharmacology,
G Hollunger, and S A Persson
April 1970, The Journal of pharmacy and pharmacology,
G Hollunger, and S A Persson
August 1969, Archives internationales de pharmacodynamie et de therapie,
G Hollunger, and S A Persson
September 1969, Brain research,
G Hollunger, and S A Persson
April 1977, Life sciences,
G Hollunger, and S A Persson
November 1978, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics,
Copied contents to your clipboard!